Clinical Trial Update: A Study of E7050 in Combination With E7080 in Participants With Advanced Solid Tumors (Dose Escalation) and in Participants With Recurrent Glioblastoma or Unresectable Stage III or Stage IV Melanoma After Prior Systemic Therapy (Expansion Cohort and Phase 2) [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 study of E7050 in combination with E7080 in advanced solid tumors and specific recurrent/unresectable cancers; the trial status is terminated with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Melanoma
• Solid Tumors

Drugs mentioned

• E7050
• E7080 (lenvatinib)

Snippet

Sponsor: Eisai Inc. | Conditions: Advanced Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2021-06-08